Healthtronics Inc

Healthtronics — Healthtronics Surgical Services — Investor Presentation (February 2004)

34 slides from Healthtronics's investor presentation, Feb 2, 2004

  1. Slide 1: HealthTronics Surgical Services, Inc.

    Slide 1: HealthTronics Surgical Services, Inc.

    EALTHT RONIC SURGICAL SERVICES, INC. A Leading Provider of Orthopaedic and Urologic Non-Invasive Surgical Services

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties or other factors which may cause actual results, performance or ach

  3. Slide 3: Company Profile

    Slide 3: Company Profile

    Company Profile A leading provider of non-invasive urologic services «= Lithotripsy — Leading treatment for kidney stones = TUMT - Treatment of benign prostate enlargement = Cryotherapy - Treatment for prostate cancer The pioneer of Orthotripsy® ESWS in the U.S. = OssaTron® is the first FDA approved

  4. Slide 4: Corporate Strategy

    Slide 4: Corporate Strategy

    Corporate Strategy « Build infrastructure to support growth of Orthotripsy® nationwide = Continue generating cash flow and earnings from urology operations = Establish new businesses by leveraging existing base of national urology network 4 FexniTroncy

  5. Slide 5: Market Drivers

    Slide 5: Market Drivers

    Market Drivers = Growing demand for non-invasive and minimally invasive surgical procedures = Trend from health care facilities to outsource specialized services « Aging of U.S. population and promotion of healthy, active lifestyle 5 FexniTroncy

  6. Slide 6: Multiple Revenue Sources

    Slide 6: Multiple Revenue Sources

    Multiple Revenue Sources = Turnkey Clinical and Technical Services provided to doctors, hospitals and patients = Management Fees from Partnerships = Sale of Equipment — LithoTron®, OssaTron® = Sale of Consumables = Equipment Maintenance and Support = Syndication Profits 6 FexniTroncy

  7. Slide 7: Lithotripsy

    Slide 7: Lithotripsy

    Lithotripsy 7 FexniTroncy

  8. Slide 8: Lithotripsy Economics

    Slide 8: Lithotripsy Economics

    Lithotripsy Economics = Average location now treating 400 cases per year a Reimbursement averages $2,000 per procedure = Operating costs average $300,000 per year = Partnership operating profits average $500,000 per year = HealthTronics Surgical Services’ average partnership stake is approximately 3

  9. Slide 9: Prostate Services

    Slide 9: Prostate Services

    Prostate Services = Transurethral Microwave Therapy = Treatment of benign prostate enlargement = Outpatient procedure = One of the largest providers in the U.S., projected to treat approximately 3,300 patients in 2004 = Partnership model does not generally apply = Cryosurgery (controlled freezing) M

  10. Slide 10: The Prostate Problem

    Slide 10: The Prostate Problem

    +> The Prostate Problem Epidemic? FexniTroncy

  11. Slide 11: Concerns

    Slide 11: Concerns

    Concerns Patient Concerns Payor Concerns = Efficacy = Cost = Potency = Cost = Incontinence = Cost = Time = Cost = Complications = Cost 11

  12. Slide 12: BPH — Benign Prostatic Hypertrophy

    Slide 12: BPH — Benign Prostatic Hypertrophy

    BPH — Benign Prostatic Hypertrophy = Non-cancerous enlargement of the prostate = Affects 50% of men over age 60 = Symptoms associated with restricted flow of urine « Multiple treatments available

  13. Slide 13: HealthTronics BPH Treatment Options

    Slide 13: HealthTronics BPH Treatment Options

    HealthTronics BPH Treatment Options = Trans Urethral Microwave Treatment (TUMT) = In office = Single treatment — 30 minutes = Good Medicare reimbursement « Laser Excision In surgery center Single treatment — 1 hour Doctors like it (more like surgery) Anticipate better outcomes than TUMT a3

  14. Slide 14: Prostate Cancer

    Slide 14: Prostate Cancer

    Prostate Cancer = Second most common cancer in males = 230,000 new cases per year in the U.S. = PSA has changed the management of prostate cancer = Five treatment options Surgery Radiation Cryosurgery Medication HIFU 14 FexniTroncy

  15. Slide 15: Efficacy Comparison of Treatment Options

    Slide 15: Efficacy Comparison of Treatment Options

    Efficacy Comparison of Treatment Options | for Stage T1-T2 Prostate Cancer : 8 a bRFS | | | i} 15 CFeATHTRON

  16. Slide 16: Non-Efficacy Comparisons

    Slide 16: Non-Efficacy Comparisons

    Non-Efficacy Comparisons* Surgery Radiation Cryo Medications HIFU Potency iy 2 1 1 2 Incontinence 1 3 2 3 3 Time 2 0 3 0 3 Complications all 2 2 2 2 5 7 8 6 10 Estimated Treatment Cost $12,000 $25,000 $12,000 $50,000 $12,000 *Dr. Wheelock’s evaluation. Rating system: 0-awful; 1-poor; 2-accentable: 3

  17. Slide 17: Orthotripsy with OssaTron

    Slide 17: Orthotripsy with OssaTron

    Orthotripsy® willirs OssaTron®

  18. Slide 18: Orthotripsy with OssaTron

    Slide 18: Orthotripsy with OssaTron

    Orthotripsy® with OssaTron® [Video clip omitted] Overview of the OssaTron™ orthopaedic extracorporeal shock wave device, basic explanation of the principle of shock waves and of how the OssaTron generates and uses shock waves to treat chronic tendon- opathies such as plantar fasciitis and lateral ep

  19. Slide 19: OssaTron Treatment for Chronic Plantar Fasciitis

    Slide 19: OssaTron Treatment for Chronic Plantar Fasciitis

    OssaTron® Treatment for 7 Chronic Plantar Fasciitis = American Podiatric Medical Association estimates over 17 million cases of heel pain in U.S. per year = Over 17,000 patients treated to date in U.S. by HealthTronics = HealthTronics patient history (2000 to present) demonstrates a re-treatment rat

  20. Slide 20: OssaTron Treatment for Chronic Lateral Epicondylitis

    Slide 20: OssaTron Treatment for Chronic Lateral Epicondylitis

    OssaTron® Treatment for 7 Chronic Lateral Epicondylitis = More than “tennis” elbow = Opens up orthopaedic market for OssaTron® = Procedure easily learned by doctor = Minimal complications = In double-blind, placebo-controlled clinical trial, the FDA concluded treatment is safe and effective = Traini

  21. Slide 21: Orthopaedic US Market Opportunity

    Slide 21: Orthopaedic US Market Opportunity

    Orthopaedic US Market 7 Opportunity Estimated # of Estimated Condition Cases perYear Market Size Heel Spurs 250,000 $500 Million Tennis Elbow 250,000 $500 Million Achilles Tendonitis 100,000 $250 Million Patellar Tendonitis 100,000 $250 Million Shoulder Tendonitis 100,000 $250 Million Delayed Union

  22. Slide 22: Orthotripsy vs. Traditional Surgery for Plantar Fasciitis

    Slide 22: Orthotripsy vs. Traditional Surgery for Plantar Fasciitis

    Orthotripsy® vs. Traditional Surgery for Plantar Fasciitis Anesthesia Procedure Time Incision Post-op Status Complications Recovery Time Post-op Analgesia Orthotripsy® Local or IV sedation < 30 Minutes No Heel pad Bruising, occasional slight numbness 2-3 Days Minimal 22 Traditional Surger ba] Genera

  23. Slide 23: Growing Clinical Acceptance and Clinical Data

    Slide 23: Growing Clinical Acceptance and Clinical Data

    Growing Clinical Acceptance 5 and Clinical Data = Significant number of positive clinical studies published worldwide = Limited number of negative studies » ; published worldwide : | se = NO negative studies . using HealthTronics’ hae current treatment Fook filnkl = protocol 23

  24. Slide 24: OssaTron Trained Physicians

    Slide 24: OssaTron Trained Physicians

    OssaTron Trained Physicians

  25. Slide 25: Media Coverage

    Slide 25: Media Coverage

    \ Coverage pg RUNNER'S/ORLD PREVENTION

  26. Slide 26: Treatment Locations

    Slide 26: Treatment Locations

    Treatment Locations 180 160 140 120 100 1997 1998 1999 2000 2001 2002 2003E BLithotripsy H Orthotripsy OProstate 26 EALTHTRON'

  27. Slide 27: Service Locations

    Slide 27: Service Locations

    Service Locations Ce Te pee FexniTroncy

  28. Slide 28: Patient Treatments

    Slide 28: Patient Treatments

    Patient Treatments 50,000 1,470 40,000 30,000 20,000 10,000 1998 1999 2000 2001 2002 =. 2003E (est.) wLithotripsy @ Orthopaedics mProstate 28 FleaniTronep

  29. Slide 29: Revenues

    Slide 29: Revenues

    Revenues {in thousands) $85,000- 100,000 $87,192 $90,000 80,000 60,000 $43,882 40,000 20,000 1996 1997 1998 1999 2000 2001 2002 2003E 29 CeatuTron

  30. Slide 30: Fully Diluted Earnings per Share

    Slide 30: Fully Diluted Earnings per Share

    Fully Diluted | Earnings per Share $0.45-$0.55 $0.55* 1996 1997 1998 1999 2000 2001 2002 2003E * $.73, Gamonsolof $0fromdspostionorus. 30 EALTHTRONI

  31. Slide 31: Management

    Slide 31: Management

    Management Argil Wheelock, M.D. - Chairman & CEO since 1996 20 years experience in physician-related business activities. Practicing urologist, 1979- 1996, Public company consultant 1991-1996 Martin McGahan — President and COO; Previous CFO since 2001 15 years experience in healthcare finance, busin

  32. Slide 32: Stock Profile

    Slide 32: Stock Profile

    Stock Profile Nasdaq: HTRN Share Price: $6.75 52 Week Range: $11.67 — $5.10 Shares Outstanding: 11.6 Million Market Capitalization: $78.2 Million Average Daily Volume: 84,000 2001 EPS: $0.28 2002 EPS: $0.55* 2003 Est. EPS: $0.45 - $0.55 “GAAP earnings were $.73, which includes 39 Gea gain on sale of

  33. Slide 33: Reasons to Invest in HTRN

    Slide 33: Reasons to Invest in HTRN

    Reasons to Invest in HTRN Rapidly growing innovator with the first FDA- approved device for orthopaedic shock wave surgery Addressing large untapped orthopaedic market that could exceed $2 billion Steady cash flow from kidney lithotripsy business inancing new opportunities in orthopaedics and urolog

  34. Slide 34: Searchable text section of graphics

    Slide 34: Searchable text section of graphics

    Searchable text section of graphics shown above [ LOG O] A Leading Provider of Orthopaedic and Urologic Non-Invasive Surgical Services Saf e Harbor Statement This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forwa

Source: SEC EDGAR · 8-K filed Feb 2, 2004

More decks from Healthtronics Inc